Ivonescimab's progression-free survival benefit fades over time
New data from Akeso and Summit's lung cancer drug ivonescimab show a diminishing effect on delaying tumor progression. The findings raise questions about the drug's durability. The update was part of a broader biotech news roundup.
Related stories
PBMs agree to show TrumpRx pricing · Healthcare systems
Ivonescimab's long-term data shows reduced benefit in Chinese lung cancer patients · Cancer research
Debate over optimal cancer drug dosing intensifies · Cancer research
AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit.” Browse more stories.